UK Botulinum Toxin Market: By Product Type (Botulinum Toxin A, Botulinum Toxin B), By Distribution Channel (Retail Pharmacies, Beauty Clinics, Others), and Country

UK Botulinum Toxin Market size was valued at US$ 128.2 million in 2023 and is poised to grow at a CAGR of 14.4 % from 2024-2030. Botulinum toxin belongs to a neurotoxin class of medication that interferes with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The increased popularity of aesthetic procedures, both invasive and non-invasive cosmetic treatments are expected to drive the market. According to a 2019 BAAPS Association report, there is an increase in demand for non-surgical therapies in the nation, and the group claims that non-invasive procedures for males became more popular in 2018.

Moreover, the treatment acquired wide acceptance because they need less recovery time, leaves no scars, are less expensive, more accurate, and have fewer risks than open treatments. Furthermore, due to an increase in the geriatric population, an increase in botulinum toxin procedures, and a rise in people's awareness of aesthetics, it is projected that demand for botulinum toxin will rise internationally throughout the projection period. But the adoption of “The Botulinum Toxin and Cosmetic Fillers (Children) Act 2021” in the UK to prevent the administration of botulinum toxin, or a filler by way of injection for a cosmetic purpose, to a person under-18 in England hinders the growth of the market. However, the emergence of strong pipeline candidates, increased spending on the construction of healthcare infrastructure, rising affordability, and modifications to reimbursement policies to cover botulinum injections all contribute to the expansion of the market over forecasted years.

Key Developments

• In July 2021, Allergan, an AbbVie company, announced the U.S. Food and Drug Administration (FDA) approved its label expansion of BOTOX® to include eight new muscles for the treatment of upper limb spasticity in adults.
• In July 2020, Allergan, an AbbVie company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.